We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Cencora, Inc. (COR) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Cencora (COR - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Cencora is one of 949 individual stocks in the Medical sector. Collectively, these companies sit at #3 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Cencora is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for COR's full-year earnings has moved 1.3% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, COR has gained about 61.2% so far this year. Meanwhile, stocks in the Medical group have gained about 4.8% on average. This shows that Cencora is outperforming its peers so far this year.
Boston Scientific (BSX - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 8.2%.
The consensus estimate for Boston Scientific's current year EPS has increased 2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Cencora belongs to the Medical Services industry, a group that includes 63 individual stocks and currently sits at #152 in the Zacks Industry Rank.
On the other hand, Boston Scientific belongs to the Medical - Products industry. This 83-stock industry is currently ranked #160.
Going forward, investors interested in Medical stocks should continue to pay close attention to Cencora and Boston Scientific as they could maintain their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Cencora, Inc. (COR) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Cencora (COR - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Cencora is one of 949 individual stocks in the Medical sector. Collectively, these companies sit at #3 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Cencora is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for COR's full-year earnings has moved 1.3% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, COR has gained about 61.2% so far this year. Meanwhile, stocks in the Medical group have gained about 4.8% on average. This shows that Cencora is outperforming its peers so far this year.
Boston Scientific (BSX - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 8.2%.
The consensus estimate for Boston Scientific's current year EPS has increased 2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Cencora belongs to the Medical Services industry, a group that includes 63 individual stocks and currently sits at #152 in the Zacks Industry Rank.
On the other hand, Boston Scientific belongs to the Medical - Products industry. This 83-stock industry is currently ranked #160.
Going forward, investors interested in Medical stocks should continue to pay close attention to Cencora and Boston Scientific as they could maintain their solid performance.